5.28

2.52% 0.13

After Hours: 5.26 -0.02 -0.38%

Corvus Pharmaceuticals Inc (CRVS)

Overview News Price History Option Chain Financials Discussions Forecast

Corvus Pharmaceuticals Inc stock is traded at $5.28, with a volume of 114.46K. It is up +2.52% in the last 24 hours and up +17.86% over the past month. Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Previous Close:

$5.15

Open:

$5.16

24h Volume:

114.46K

Relative Volume:

0.31

Market Cap:

$330.27M

Revenue:

Net Income/Loss:

$-27.03M

P/E Ratio:

-6.2857

EPS:

-0.84

Net Cash Flow:

$-23.97M

1W Performance:

-2.94%

1M Performance:

+17.86%

6M Performance:

+196.63%

1Y Performance:

+261.64%

1-Day Range:

$5.03

$5.29

1-Week Range:

$4.98

$5.41

52-Week Range:

$1.05

$6.15

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name

Corvus Pharmaceuticals Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(650) 900-4520

Address

863 MITTEN ROAD, BURLINGAME, CA

Employee

Twitter

Next Earnings Date

2024-08-06

Latest SEC Filings

CRVS's Discussions on Twitter

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-18-23	Initiated	Oppenheimer	Outperform
Dec-01-21	Resumed	Jefferies	Buy
May-27-21	Initiated	Cantor Fitzgerald	Overweight
Feb-10-21	Downgrade	Mizuho	Buy → Neutral
Sep-12-19	Initiated	Mizuho	Buy
May-29-19	Initiated	ROTH Capital	Buy
Aug-24-17	Upgrade	Credit Suisse	Underperform → Neutral
May-01-17	Downgrade	Credit Suisse	Neutral → Underperform
Apr-18-16	Initiated	Credit Suisse	Outperform
Apr-18-16	Initiated	Guggenheim	Buy

View All

Corvus Pharmaceuticals Inc Stock (CRVS) Latest News

Sep 28, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Downgraded to "Sell" at StockNews.com - MarketBeat

Sep 28, 2024

Sep 26, 2024

When the Price of (CRVS) Talks, People Listen - Stock Traders Daily

Sep 26, 2024

Sep 24, 2024

Croda International (OTCMKTS:COIHD) Sets New 52-Week Low at $26.75 - Defense World

Sep 24, 2024

Cormorant Asset Management's Strategic Acquisition in Corbus Pha - GuruFocus.com

Sep 24, 2024

Corcept Therapeutics (NASDAQ:CORT) Sets New 52-Week High at $43.81 - Defense World

Sep 24, 2024

Cormorant asset management buys $7m in Corbus Pharmaceuticals stock By Investing.com - Investing.com Canada

Sep 24, 2024

Closing Figures Unveiled: Corvus Pharmaceuticals Inc (CRVS) Drop -7.95, Closes at 5.44 - The Dwinnex

Sep 24, 2024

A stock that deserves closer examination: Corvus Pharmaceuticals Inc (CRVS) - US Post News

Sep 24, 2024

Are Smart Investors Making the Right Decision? Corbus Pharmaceuticals Holdings Inc (CRBP) - SETE News

Sep 24, 2024

Top investors say Corcept Therapeutics Inc (CORT) ticks everything they need - SETE News

Sep 24, 2024

Samlyn Capital LLC Has $11.14 Million Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat

Sep 24, 2024

Wall Street Analyst Initiated Core Scientific Inc [CORZ]. What else is Wall St. saying - The DBT News

Sep 24, 2024

Where are the Opportunities in (CRBP) - Stock Traders Daily

Sep 24, 2024

Corcel shares drop as explorer raise funds and ups exposure in Angola - Proactive Investors USA

Sep 24, 2024

Sep 23, 2024